Enveric Biosciences Unveils Promising Preclinical Data on EB-003 for Anxiety and Depression

Enveric Biosciences recently presented promising preclinical data at the European Behavioral Pharmacology Society’s Biennial Workshop, showcasing their latest findings on EB-003, a novel neuroplastogenic small-molecule therapeutic for anxiety and depression. The research highlights key behavioral outcomes in mouse models, including the head twitch response (HTR), marble burying, and sucrose preference tests, which are indicative of anxiety and depression. Notably, EB-003 demonstrates beneficial neuroplastogenic responses without inducing hallucinations, a significant advancement in mental health treatment.

Dr. Facchini expressed pride in presenting these findings, emphasizing the potential of EB-003 to advance to clinical trials. Enveric announced that EB-003 has shown oral bioavailability and therapeutic brain exposure, with plans to file an Investigational New Drug (IND) application by the third quarter of 2025, aiming to begin clinical development by the end of that year.

Enveric Biosciences is a biotechnology company focused on developing innovative treatments for depression, anxiety, and addiction disorders. Utilizing their proprietary Psybrary™ platform, Enveric has built a strong intellectual property portfolio targeting mental health issues. Their lead program, EB-003, aims to enhance neuroplasticity without causing hallucinations, offering a first-in-class treatment approach. Enveric is also developing EB-002, a synthetic prodrug of psilocin, for psychiatric disorders. Headquartered in Naples, FL, with offices in Cambridge, MA, and Calgary, AB, Canada, Enveric continues to push the boundaries of mental health therapeutics.

For more information, please visit Enveric's website.

Forward-Looking Statements

This release includes forward-looking statements regarding future events or performance. Such statements are identified by words like "plans," "expects," "anticipates," and similar expressions. These statements are based on current management beliefs and assumptions, and actual results may differ due to various factors, including the ability to finalize agreements, conduct successful clinical programs, and secure necessary approvals. For a detailed discussion of risks and uncertainties, refer to Enveric’s filings with the Securities and Exchange Commission.